不同分期前列腺癌患者循环肿瘤细胞中肿瘤进展相关基因的表达
这项前瞻性研究纳入81例不同分期前列腺癌患者,采用AdnaTest检测循环肿瘤细胞(CTC)及其干细胞和上皮间质转化(EMT)相关转录本。结果显示CTC阳性率在转移性疾病患者中显著更高,且晚期患者CTC中雄激素受体(AR)和胸苷酸合成酶(TYMS)表达更常见,而c-met和c-kit表达罕见。
要点
- AdnaTest ProstateCancerDetect阳性主要见于转移性前列腺癌患者。
- AR和TYMS在晚期患者CTC中表达频繁,c-met和c-kit表达罕见。
- CTC分析用于晚期前列腺癌个体化治疗决策的价值尚待确定。
核心结论
- AdnaTest ProstateCancerDetect主要在转移性疾病患者中呈阳性结果。
- AR和TYMS表达在晚期患者CTC中常见,而c-met和c-kit基因表达仅见于小部分患者。
- CTC分析作为晚期前列腺癌个体化治疗决策因素的意义尚待确定。
研究设计与样本
- 前瞻性研究纳入2014年7月至2015年2月期间接受治疗的81例前列腺癌患者。
- A组18例(22.2%)低危临床局限期,B组25例(30.9%)高危临床局限期,C组11例(13.6%)转移性去势敏感(mCSPC),D组27例(33.3%)转移性去势抵抗(mCRPC)。
- 所有病例均行AdnaTest ProstateCancer及AdnaTest StemCell/EMT检测。
- 采用特异性聚合酶链反应检测CTC中雄激素受体(AR)、c-met、c-kit和胸苷酸合成酶(TYMS)表达。
主要发现
- AdnaTest ProstateCancer阳性在A、B、C、D组分别为3例(16.7%)、2例(8.0%)、6例(54.5%)、19例(70.5%)(P < 0.01,卡方检验)。
- AdnaTest EMT阳性在A、B、C、D组分别为0例(0.0%)、0例(0.0%)、1例(9.1%)、2例(7.4%),组间无显著差异。
- AdnaTest StemCell阳性在A、B、C、D组分别为5例(27.8%)、4例(16.0%)、3例(27.3%)、11例(40.7%),组间无显著差异。
- CTC表达TYMS在C组和D组分别为44.4%和50.0%,非转移性疾病为13.9%;表达AR分别为18.2%和25.9%,非转移性疾病为0.0%(均P < 0.05)。
- c-kit和c-met表达罕见,仅2例患者任一标志物阳性。
临床怎么用
- 对于转移性前列腺癌患者,可考虑采用AdnaTest ProstateCancerDetect进行CTC检测。
- 在晚期患者中可评估CTC的AR和TYMS表达,但c-met和c-kit检测价值有限。
- CTC分析用于个体化治疗决策前需进一步研究确定其临床意义。
局限性
- 研究样本量有限,各组例数较少。
- CTC分析作为治疗决策因素的意义尚未确定,需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the presence of circulating tumour cells (CTCs) at different stages of prostate cancer using the AdnaTest® ProstateCancerDetect kit (Qiagen). Moreover, we aimed to assess the expression of transcripts that are specific for cancer stem cells (AdnaTest StemCell) and epithelial-mesenchymal transition (EMT) in CTCs (AdnaTest EMT), as well as additional genes that are known to promote prostate cancer progression. PATIENTS AND METHODS: In this prospective study, we included 81 patients who underwent treatment for prostate cancer between 07/2014 and 02/2015, including: Group A, 18 patients (22.2%) with low-risk clinically localised prostate cancer; Group B, 25 patients (30.9%) with high-risk clinically localised prostate cancer; Group C, 11 patients (13.6%) with metastatic castration-sensitive prostate cancer (mCSPC); and Group D, 27 patients (33.3%) with metastatic castration-resistant prostate cancer (mCRPC). AdnaTest ProstateCancer and AdnaTest StemCell/EMT were performed in all cases. In addition, expression of the androgen receptor (AR), c-met, c-kit and thymidylate synthase (TYMS) in CTCs was assessed using specific polymerase chain reaction assays. RESULTS: A positive AdnaTest ProstateCancer was present in three (16.7%), two (8.0%), six (54.5%) and 19 (70.5%) patients in groups A, B, C and D, respectively (P < 0.01, chi-squared test). The AdnaTest EMT and AdnaTest StemCell were positive in zero (0.0%), zero (0.0%), one (9.1%), and two (7.4%); and in five (27.8%), four (16.0%), three (27.3%), and 11 (40.7%) patients in groups A, B, C and D, respectively, with no significant differences noted between groups. CTCs expressing TYMS (44.4% and 50.0% vs 13.9%) or AR (18.2% and 25.9% vs 0.0%) were seen more commonly in patients in groups C and D vs patients with non-metastatic disease (all P < 0.05). Expression of c-kit and c-met were rare events, with only two patients positive for either marker. CONCLUSIONS: AdnaTest ProstateCancerDetect exhibits positive results mainly in patients with metastatic disease. Expression of AR and TYMS are frequent events in CTCs of patients with advanced disease, whereas c-met and c-kit gene expression is seen in only a small proportion of patients. The implications of these results for the use of CTC analysis as a decision factor for personalised treatment strategies in advanced prostate cancer remain to be determined.
引用
- Russo GI, Bier S, Hennenlotter J, et al. Expression of tumour progression-associated genes in circulating tumour cells of patients at different stages of prostate cancer. BJU Int. 2018. PMID: 29542849. doi:10.1111/bju.14200
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。